Uckun, Fatih M

The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism. [electronic resource] - Leukemia & lymphoma Sep 2003 - 1569-77 p. digital

Publication Type: Comparative Study; Journal Article

1042-8194

10.3109/10428190309178781 doi


Adenosine Diphosphate--pharmacology
Agammaglobulinaemia Tyrosine Kinase
Amides--pharmacology
Animals
Aspirin--pharmacology
Bleeding Time
Catalytic Domain--drug effects
Collagen--antagonists & inhibitors
Drug Design
Drug Evaluation, Preclinical
Enzyme Inhibitors--pharmacology
Fibrinolytic Agents--pharmacology
Humans
Janus Kinase 3
Male
Mice
Mice, Inbred ICR
Nitriles--pharmacology
Peptide Fragments--pharmacology
Platelet Activation--drug effects
Platelet Aggregation--drug effects
Platelet Aggregation Inhibitors--pharmacology
Platelet Membrane Glycoproteins--drug effects
Protein-Tyrosine Kinases--antagonists & inhibitors
Pulmonary Embolism--chemically induced
Quinazolines--pharmacology
Receptors, Collagen--drug effects
Signal Transduction--drug effects
Thrombin--pharmacology
Thromboembolism--chemically induced
Thromboplastin--toxicity